Загрузка...
Would Tirofiban Have Been Shown Non-Inferior to Abciximab Had the TENACITY Trial Not Been Terminated for Financial Reasons?
OBJECTIVES: To investigate whether tirofiban would have been non-inferior to abciximab had the trial completed enrollment, and we place the termination of this trial in a broader research ethics context. BACKGROUND: TENACITY was terminated by the sponsor for financial reasons. At the time, event rat...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4156852/ https://ncbi.nlm.nih.gov/pubmed/23379785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1540-8183.2013.12020.x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|